Investors looking at Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart, News: TSX:DN... Read More
Robust M&A activity drove overall sector valuations in fiscal 2013, and we believe expectations ... Read More
Byron Capital analyst Douglas Loe says the price Canadian pharma giant Valeant Pharmaceutical... Read More
2012 was a good year for Cipher Pharmaceuticals (TSX:DND) The specialty pharma, which boasts three c... Read More
Investors haven’t been crying over the performance of TearLab, shares of the company are up mo... Read More
Shares of Cipher Pharmaceuticals (TSX:DND) are pulling back today, but investor interest in the comp... Read More
Share
